乐普医疗公告，2025年上半年营业收入33.69亿元，同比下降0.43%。净利润6.91亿元，同比下降 0.91%。 ...

乐普（北京）医疗器械股份有限公司 2025 年半年度报告全文 乐普（北京）医疗器械股份有限公司 2025 年半年度报告 2025-070 二零二五年八月 1 乐普（北京）医疗器械股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人蒲忠杰、主管会计工作负责人王泳及会计机构负责人(会计主 管人员)李韫声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 请投资者注意阅读本报告第三节管理层讨论与分析之第十项"公司面临 的风险和应对措施"中对公司风险提示的相关内容。 公司经本次董事会审议通过的利润分配预案为：以 2025 年半年度权益分 派方案未来实施时股权登记日的总股本，扣减已回购股份后的股本 1,843,395,691 股为基数，向全体股东每 10 股派发现金红利 1.6275 元（含 税），送红股 0 股（含税），不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | ...

Core Viewpoint - Lepu Medical's stock price has shown a slight increase, reflecting market interest and potential growth in the medical device sector [1] Company Overview - Lepu Medical's latest stock price is 18.40 yuan, up by 0.37 yuan from the previous trading day [1] - The stock reached a high of 18.87 yuan and a low of 18.00 yuan during the trading session, with a total trading volume of 5.75 million shares and a transaction value of 1.063 billion yuan [1] - The company specializes in the research, production, and sales of medical devices, focusing on cardiovascular intervention and cardiac rhythm management [1] - Lepu Medical has established a comprehensive product line in niche markets through continuous innovation and technological accumulation [1] Recent Developments - Lepu Medical's affiliated company, Ruijian Medical, is currently undergoing IPO review by the Beijing Stock Exchange [1] - The review process includes inquiries regarding related party transactions and business independence [1] - Since 2022, Lepu Medical has become one of the top five customers of Ruijian Medical, raising regulatory concerns about the transaction amounts and accounts receivable ratios [1]

Core Viewpoint - The research activity in the field of biomedical materials in China has been declining from 2014 to 2024, with a decrease in the number of related papers published from 258 to 152 [3]. Group 1: Definition and Overview - Biomedical materials are defined as high-tech materials used for diagnosing, treating, repairing, or replacing human tissues and organs, categorized by their applications such as bone, soft tissue, cardiovascular, and medical membrane materials [1]. Group 2: Research Trends - The number of papers published in the biomedical materials field has shown a downward trend, indicating a decrease in research interest over the years [3]. - As of July 2025, higher education institutions are the primary contributors to the literature in this field, with Tianjin University leading by publishing 102 related papers [5]. Group 3: Research Themes - Medical polymer materials are identified as a popular research theme within the biomedical materials sector, alongside composite materials [9]. - Biomedical engineering is recognized as a prominent research discipline in this field, with significant contributions from organic chemistry, metallurgy, and metal processing [11].

特此公告。 证券代码：300003 证券简称：乐普医疗 公告编号：2025-065 乐普（北京）医疗器械股份有限公司 关于归还用于暂时补充流动资金的闲置募集资金公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称：公司）于2024年8月23 日召开第六届董事会第九次会议和第六届监事会第七次会议，审议通过了《关于 使用部分闲置募集资金暂时补充流动资金》的议案，同意公司在保证募集资金投 资项目资金使用的前提下，使用闲置募集资金不超过人民币60,000万元用于暂时 补充流动资金，使用期限自董事会审议通过之日起不超过12个月，到期归还至 募集资金专用账户，具体内容详见公司于2024年8月24日在巨潮资讯网披露的 《关于使用部分闲置募集资金暂时补充流动资金的公告》（公告编号：2024-088）。 2025年8月20日，公司已将用于暂时补充流动资金的闲置募集资金60,000万 元归还至公司募集资金专用账户，使用期限未超过12个月，公司已将上述募集 资金的归还情况通知了公司保荐机构。 乐普（北京）医疗器械股份有限公司 董事会 二○ ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-064 | | | 是否为控股 | | 占其所 | 占公司 | 是 否 | 为 | 是否为 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 质权人 | 股东 名称 | 股东或第一 大股东及其 | 本次质押数 量（股） | 持股份 | 总股本 | 限售股 | | 补充质 | 质押起始日 | 质押到期日 | | 质押用途 | | | | 一致行动人 | | 比例 | 比例 | | | 押 | | | | | | 中国银河 | 蒲忠杰 | 是 | 32,000,000 | 7.02% | 1.70% | 高管锁 定股 | | 否 | 2025 年 8 月 19 日 | 无固定期限 | 证券股份 有限公司 | 偿还债务 | 1 三、股份累计质押情况 乐普（北京）医疗器械股份有限公司 关于控股股东部分股权质押及解除质押的公告 公司控股股东蒲忠杰先生及其一致行动人保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误 ...

Group 1 - The A-share market showed mixed results, with the medical device ETF fund (159797) rising nearly 1%, marking a strong push for five consecutive days of gains [1] - The medical device ETF fund (159797) received a net subscription of 12 million units during the day, achieving a net inflow for 12 consecutive days, totaling over 130 million yuan [1] - Major stocks within the medical device ETF fund saw significant gains, including Mindray Medical up 4.35% and Hotgen Biotech up 6% [2][5] Group 2 - Recent high-level research in Beijing emphasized the need for increased high-quality technological supply and policy support in the biopharmaceutical industry, aiming to enhance the quality and efficiency of drug development [2] - The total bid amount for medical devices in July reached 12.643 billion yuan, a year-on-year increase of 20%, with a total of 96.785 billion yuan for the first seven months, reflecting a 57% year-on-year growth [3] Group 3 - The brain-computer interface industry is expected to accelerate due to supportive policies, with a target for key technological breakthroughs by 2027 [4] - The global market for brain-computer interfaces in medical applications is projected to reach 40 billion USD by 2030 and exceed 145 billion USD by 2040 [6] Group 4 - The medical device ETF fund (159797) covers core areas of medical devices, including high-value consumables and in vitro diagnostics, with the top ten weighted stocks accounting for over 44% of the fund [7]

Group 1 - The medical device sector is experiencing a strong performance, with the CSI All Medical Device Index rising by 1.41% as of August 21, 2025, and notable stocks such as Meihua Medical increasing by 14.12% [1] - The Medical Device ETF (159797) has shown a consistent upward trend, achieving a 1.55% increase over the past week and a 1.17% rise on the day of reporting [1] - The Medical Device ETF has seen significant liquidity, with a turnover rate of 7.13% and nearly 20 million yuan in trading volume [1] Group 2 - The Medical Device ETF has reached a new high in scale at 255 million yuan and a new high in shares at 300 million, indicating strong investor interest [2] - Over the past 11 days, the ETF has experienced continuous net inflows, totaling 122 million yuan, with a peak single-day inflow of 31.28 million yuan [2] Group 3 - Recent government initiatives emphasize the importance of high-quality technological supply and policy support for the biopharmaceutical industry, aiming to enhance the quality and efficiency of medical products [5] - The total bid amount for medical devices in July reached 12.643 billion yuan, reflecting a year-on-year growth of 20%, with a total of 96.785 billion yuan for the first seven months, marking a 57% increase [5] - The Ministry of Industry and Information Technology has issued guidelines to promote the innovation of brain-computer interface technology, aiming for breakthroughs by 2027 [5] Group 4 - The brain-computer interface industry is expected to see significant growth driven by technological innovation, policy support, and capital investment, particularly in healthcare and consumer markets [6] - The Medical Device ETF encompasses a wide range of sectors, including high-value consumables and in-vitro diagnostics, with the top ten weighted stocks accounting for over 44% of the fund [6]

Core Viewpoint - Lepu Medical's stock closed at 18.07 yuan, down 2.27%, with a rolling PE ratio of 236.64 times, significantly higher than the industry average of 59.49 times [1] Company Summary - Lepu Medical's main business includes medical devices, pharmaceuticals, medical services, and health management [1] - The latest quarterly report for Q1 2025 shows revenue of 1.736 billion yuan, a year-on-year decrease of 9.67%, and a net profit of 379 million yuan, down 21.44%, with a gross profit margin of 64.03% [1] Shareholder Information - As of March 31, 2025, Lepu Medical had 94,228 shareholders, an increase of 583 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Summary - The average PE ratio for the medical device industry is 59.49 times, with a median of 40.19 times, placing Lepu Medical at the 115th position in the industry ranking [2]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...